.Pharmacolibrary.Drugs.ATC.L.L01FY02 .Pharmacolibrary.Drugs.ATC.L.L01FY02| name: | NivolumabAndRelatlimab | |
| ATC code: | L01FY02 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 480 | mg |
| volume of distribution: | 6.8 | L |
| clearance: | 0.28 | L/day |
| other parameters in model implementation | ||
Nivolumab and relatlimab is a fixed-dose combination immunotherapy composed of nivolumab, a PD-1 inhibitor, and relatlimab, an anti-LAG-3 antibody. The combination is indicated for the treatment of unresectable or metastatic melanoma and has received regulatory approval for use in adults and adolescents with this condition.
Pharmacokinetics reported for adults with advanced melanoma treated in clinical trials, primarily middle-aged patients both male and female. Typical doses used in clinical trials: nivolumab 480 mg and relatlimab 160 mg, administered intravenously every 4 weeks.